Innova Biosciences Awarded EU Grant to Develop Cancer Biomarker Discovery Platform
News Feb 18, 2009
Innova Biosciences Ltd has been awarded €455,000 of a €3,000,000 European grant. Through the PROACTIVE consortium along with Olink, Copenhagen University, Fujirebio Diagnostics AB, Uppsala University, and Integromics S.L., a high throughput plasma screening platform will be developed for the discovery of biomarkers of early stage cancer.
Innova Biosciences has had enormous success with its range of Lightning-Link™ bioconjugation products, which provide a simple method for joining biomolecules, a process carried out in thousands of research laboratories worldwide.
Innova Biosciences’ participation in the PROACTIVE consortium to develop immunodiagnostics reagents will help cement the company’s position as a world leader in bioconjugation technology.
Commenting on the EU grant Dr Nick Gee, CEO of Innova Biosciences said “We are delighted to be granted such a prestigious award which recognizes Innova’s proprietary knowledge and expertise. Participating in the development of a new immunodiagnostic platform that will facilitate early stage cancer detection is an exciting application of our technology, which will directly benefit human health.”
Chinese researchers have developed interfacially polymerized porous polymer particles for low- abundance glycopeptide separation. These polymer particles - with hydrophilic-hydrophobic heterostructured nanopores - can separate low-abundance glycopeptides from complex biological samples with high-abundance background molecules efficiently.